Disclosures for "Effect of Standardized Neurologic and Psychiatric Evaluation on Prognosis for Patients Diagnosed with Functional Seizures in the Epilepsy Monitoring Unit: A Quality Improvement Initiative"
-
Dr. Boylan has nothing to disclose.
-
Dr. Jolivert has nothing to disclose.
-
Ms. Wu has nothing to disclose.
-
An immediate family member of Dr. Anderson has received personal compensation for serving as an employee of Nuro Robotics.
-
Dr. Davis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GW Pharmaceuticals/Jazz Pharmaceuticals. Dr. Davis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Spark Therapeutics. Dr. Davis has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Davis has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UNEEG. Dr. Davis has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Epilepsia Open. Dr. Davis has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Pfizer. The institution of Dr. Davis has received research support from Eisai. The institution of Dr. Davis has received research support from Liminal. Dr. Davis has received publishing royalties from a publication relating to health care.
-
Dr. Gelfand has received personal compensation in the range of $0-$499 for serving as a Consultant for Aquestive. Dr. Gelfand has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Livanova. The institution of Dr. Gelfand has received research support from Aquestive. The institution of Dr. Gelfand has received research support from Xenon. The institution of Dr. Gelfand has received research support from Cerevel. The institution of Dr. Gelfand has received research support from UNEEG. The institution of Dr. Gelfand has received research support from Livanova. The institution of Dr. Gelfand has received research support from UCB. The institution of Dr. Gelfand has received research support from SK Pharma. The institution of Dr. Gelfand has received research support from Otsuka.
-
Dr. Conrad has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Epiminder. Dr. Conrad has stock in Humana. Dr. Conrad has stock in Lilly Eli. Dr. Conrad has stock in Medtronic. Dr. Conrad has stock in Merck. Dr. Conrad has stock in Nevro. Dr. Conrad has stock in Sanofi. Dr. Conrad has stock in United Health Group.